title: The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogeneic bone marrow transplantation.
abstract: BACKGROUND
  Gram-positive bacteremia (GPB) is an increasing infection after allogeneic bone marrow transplantation (BMT). Our purpose was to identify risk factors for GPB, to evaluate its impact on early mortality and morbidity, and to compare prophylactic with empirical intravenous vancomycin.
  
  
  RESULTS
  We studied 89 consecutive BMTs in adult patients. Early GPB occurred in 29% of posttransplantation episodes. T-cell depletion (odds ratio [OR]: 0.18) and vancomycin-prophylaxis (OR: 0.28) reduced the risk of GPB. Mortality at 6 weeks was not significantly different in patients with GPB (15% vs. 9.5%, P = 0.669). GPB was associated with the development of major complications, the use of amphotericin B, and prolonged neutropenia. Vancomycin prophylaxis led to an increased risk of early renal dysfunction (OR: 18.7).
  
  
  CONCLUSIONS
  GPB contributes to overall morbidity during the early post-BMT episode but has no impact on mortality. Vancomycin prophylaxis is effective to reduce GPB but has a negative effect on renal function.
authors.affiliation: BMT-Unit, Academisch Ziekenhuis Vrije Universitiet Brussel, Brussels, Belgium. igssr@az.vub.ac.be
authors.forename: R
authors.initials: R
authors.lastname: Schots
authors.forename: F
authors.initials: F
authors.lastname: Trullemans
authors.forename: I
authors.initials: I
authors.lastname: Van Riet
authors.forename: L
authors.initials: L
authors.lastname: Kaufman
authors.forename: A
authors.initials: A
authors.lastname: Hafsia
authors.forename: B
authors.initials: B
authors.lastname: Meddeb
authors.forename: Z B
authors.initials: ZB
authors.lastname: Hadj Ali
authors.forename: H
authors.initials: H
authors.lastname: Ben Abid
authors.forename: S
authors.initials: S
authors.lastname: Lauwers
authors.forename: B
authors.initials: B
authors.lastname: Van Camp
mesh_terms: D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D016470:Bacteremia / Q000209:etiology* / Q000517:prevention & control; D016026:Bone Marrow Transplantation; D015331:Cohort Studies; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D014184:Transplantation, Homologous; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin